TY - JOUR T1 - Response strategies for COVID-19 epidemics in African settings: a mathematical modelling study JF - medRxiv DO - 10.1101/2020.04.27.20081711 SP - 2020.04.27.20081711 AU - Kevin van Zandvoort AU - Christopher I Jarvis AU - Carl A B Pearson AU - Nicholas G Davies AU - CMMID COVID-19 working group AU - Timothy W Russell AU - Adam J Kucharski AU - Mark Jit AU - Stefan Flasche AU - Rosalind M Eggo AU - Francesco Checchi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/03/2020.04.27.20081711.abstract N2 - Background The health impact of COVID-19 may differ in African settings as compared to countries in Europe or China due to demographic, epidemiological, environmental and socio-economic factors. We evaluated strategies to reduce SARS-CoV-2 burden in African countries, so as to support decisions that balance minimising mortality, protecting health services and safeguarding livelihoods.Methods We used a Susceptible-Exposed-Infectious-Recovered mathematical model, stratified by age, to predict the evolution of COVID-19 epidemics in three countries representing a range of age distributions in Africa (from oldest to youngest average age: Mauritius, Nigeria and Niger), under various effectiveness assumptions for combinations of different non-pharmaceutical interventions: self-isolation of symptomatic people, physical distancing, and ‘shielding’ (physical isolation) of the high-risk population. We adapted model parameters to better represent uncertainty about what might be expected in African populations, in particular by shifting the distribution of severity risk towards younger ages and increasing the case-fatality ratio.Results We predicted median clinical attack rates over the first 12 months of 17% (Niger) to 39% (Mauritius), peaking at 2–4 months, if epidemics were unmitigated. Self-isolation while symptomatic had a maximum impact of about 30% on reducing severe cases, while the impact of physical distancing varied widely depending on percent contact reduction and R0. The effect of shielding high-risk people, e.g. by rehousing them in physical isolation, was sensitive mainly to residual contact with low-risk people, and to a lesser extent to contact among shielded individuals. Response strategies incorporating self-isolation of symptomatic individuals, moderate physical distancing and high uptake of shielding reduced predicted peak bed demand by 46% to 54% and mortality by 60% to 75%. Lockdowns delayed epidemics by about 3 months. Estimates were sensitive to differences in age-specific social mixing patterns, as published in the literature.Discussion In African settings, as elsewhere, current evidence suggests large COVID-19 epidemics are expected. However, African countries have fewer means to suppress transmission and manage cases. We found that self-isolation of symptomatic persons and general physical distancing are unlikely to avert very large epidemics, unless distancing takes the form of stringent lockdown measures. However, both interventions help to mitigate the epidemic. Shielding of high-risk individuals can reduce health service demand and, even more markedly, mortality if it features high uptake and low contact of shielded and unshielded people, with no increase in contact among shielded people. Strategies combining self-isolation, moderate physical distancing and shielding will probably achieve substantial reductions in mortality in African countries. Temporary lockdowns, where socioeconomically acceptable, can help gain crucial time for planning and expanding health service capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the following sources of funding:KvZ, CIJ and CABP: Department for International Development/Wellcome Epidemic Preparedness-Coronavirus research programme (ref. 221303/Z/20/Z). CABP: Bill and Melinda Gates Foundation (OPP1184344). FC, CIJ: UK Researchand Innovation as part of the Global Challenges Research Fund, grant number ES/P010873/1.by UK Research and Innovation as part of the Global Challenges Research Fund, grant number ES/P010873/1. TWR, SF, AJK: Wellcome Trust (grant: 206250/Z/17/Z). NGD: National Institute of Health Research (HPRU-2012-10096). MJ: Bill and Melinda Gates Foundation (INV-003174), National Institute of Health Research (16/137/109), European Commission (101003688). RMG: Health Data Research UK (grant: MR/S003975/1), Medical Research Council (grant: MC_PC 19065).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used publicly available data. ER -